Polycythemia Vera: Thick Blood, Clot Risk, and Treatment Goals

Polycythemia Vera is a chronic blood disorder in which the bone marrow makes too many red blood cells, making the blood thicker and increasing the risk of clots. With careful monitoring and individualized treatment, many people can control symptoms, reduce complications, and maintain daily activities.

Overview

Polycythemia Vera is a chronic blood disorder in which the bone marrow produces too many red blood cells. Many people also have increased white blood cells and platelets. Because red blood cells carry oxygen and make up a large part of blood volume, having too many of them can make blood thicker than usual. This may slow blood flow and increase the chance of clot formation.

Polycythemia Vera belongs to a group of conditions called myeloproliferative neoplasms. These are disorders in which blood-forming stem cells in the bone marrow grow more actively than they should. In most people with Polycythemia Vera, the condition is associated with a change in the JAK2 gene, which affects signals that control blood cell production.

The condition usually develops slowly and may be found on a routine blood test before symptoms appear. Although it is a long-term condition, treatment is available to reduce blood thickness, manage symptoms, and lower the risk of complications. The key is regular care with a hematology team and a treatment plan tailored to the person’s age, clotting history, blood counts, symptoms, and overall health.

Symptoms and How Thick Blood Affects the Body

Some people with Polycythemia Vera feel well for a long time, while others notice symptoms caused by thickened blood, changes in circulation, or an enlarged spleen. Symptoms can be mild and nonspecific, so they may be mistaken for stress, dehydration, or other common problems. A blood test is often the first clue.

Possible symptoms include headaches, dizziness, blurred vision, ringing in the ears, fatigue, shortness of breath with activity, and a feeling of pressure or fullness in the left upper abdomen due to an enlarged spleen. Some people develop redness or a flushed appearance of the face, hands, or feet. Burning pain, warmth, or redness in the hands and feet can also occur when small blood vessels are affected.

Itching, especially after a warm bath or shower, is a classic symptom. It may happen even without a visible rash. Other possible signs include night sweats, unintentional weight loss, easy bruising, or bleeding from the gums or nose. These symptoms do not always mean the disease is severe, but they should be discussed with a doctor because treatment can often improve comfort and reduce risk.

Causes and Risk Factors

Polycythemia Vera is usually caused by an acquired genetic change in a blood-forming stem cell. Acquired means the change develops during a person’s life rather than being inherited from a parent. The most common change involves the JAK2 gene, which acts like a growth signal for blood cell production. When this signal is overactive, the bone marrow may produce too many cells.

For most patients, there is no clearly preventable cause. Polycythemia Vera is not caused by lifestyle choices, and it is not contagious. It is different from secondary polycythemia, in which red blood cell levels rise because of another trigger such as chronic low oxygen, smoking-related lung disease, sleep apnea, certain tumors, or use of some hormone medicines. Distinguishing Polycythemia Vera from secondary causes is an important part of diagnosis.

Risk tends to increase with age, and the condition is more often diagnosed in adults than in children. A personal history of blood clots is an important clinical factor because it influences treatment intensity. Doctors also consider cardiovascular risk factors such as high blood pressure, diabetes, high cholesterol, and smoking because these can add to clot risk in a person whose blood is already more prone to clotting.

Diagnosis

Diagnosis begins with a complete blood count, often called a CBC. This test measures hemoglobin, hematocrit, red blood cells, white blood cells, and platelets. In Polycythemia Vera, the hematocrit and hemoglobin are typically elevated, and white blood cells or platelets may also be high. A repeat test may be needed to confirm that the abnormality is persistent and not related to dehydration or a temporary condition.

Doctors may order blood tests for the JAK2 mutation and for erythropoietin, a hormone that normally stimulates red blood cell production. In Polycythemia Vera, erythropoietin levels are often low because the body is already producing too many red blood cells without needing extra stimulation. Oxygen levels, kidney and liver tests, iron studies, and other evaluations may be used to rule out secondary causes of polycythemia.

A bone marrow biopsy may be recommended in some patients to confirm the diagnosis, assess marrow cell patterns, and help distinguish Polycythemia Vera from related myeloproliferative neoplasms. Imaging, such as ultrasound, may be used if the spleen is enlarged or if abdominal symptoms are present. Diagnosis is based on a combination of clinical findings, blood counts, molecular testing, and sometimes bone marrow results rather than on one test alone.

Treatment Goals and Options

The central treatment goal in Polycythemia Vera is to reduce the risk of blood clots while improving symptoms and maintaining a safe blood count range. A key target is lowering the hematocrit, the percentage of blood volume made up by red blood cells. Keeping hematocrit controlled helps blood flow more easily and reduces strain on the circulation.

Phlebotomy is often the first treatment used. It is a procedure similar to donating blood, in which a measured amount of blood is removed to lower the red blood cell mass. The frequency depends on the patient’s hematocrit, symptoms, and response. At the beginning, phlebotomy may be needed more often; later, it may be performed periodically as maintenance.

Low-dose aspirin may be recommended for many patients to help reduce clotting tendency, but it is not suitable for everyone. People with a high bleeding risk, stomach ulcers, certain platelet abnormalities, or other medical conditions need individualized advice. Patients should not start or stop aspirin on their own without speaking with a qualified doctor.

Some patients need medication to reduce blood cell production. This is more likely if they are older, have had a previous clot, have very high platelet or white blood cell counts, cannot tolerate frequent phlebotomy, or have significant symptoms. Commonly used options may include hydroxyurea, interferon-based therapy, or targeted medicines such as JAK inhibitors in selected cases. The choice depends on risk level, side effect profile, pregnancy considerations, other illnesses, and treatment goals.

Living With Polycythemia Vera: Prevention and Self-Care

Self-care cannot replace medical treatment, but it can support circulation and overall health. Patients are usually encouraged to stay well hydrated, remain physically active within their ability, and avoid long periods of immobility. During long travel, standing, stretching, and walking when possible may help maintain blood flow. Any travel plan should be discussed with the treating doctor if the patient has a history of clots or active symptoms.

Managing cardiovascular risk factors is especially important. This includes controlling blood pressure, cholesterol, and blood sugar, and avoiding tobacco. Smoking can worsen blood vessel health and may further increase clot risk. A balanced diet, regular movement, and weight management when needed can help support the heart and blood vessels.

Patients should tell their healthcare team before surgery, dental procedures, or new medications, including supplements. Polycythemia Vera can affect both clotting and bleeding risk, so procedures may require planning. It is also helpful to keep a record of blood counts, medications, phlebotomy dates, symptoms, and any clotting or bleeding events. This gives the care team a clearer picture of how the condition is changing over time.

Possible Complications and Long-Term Monitoring

The main concern in Polycythemia Vera is blood clot formation. Clots can occur in veins or arteries and may affect the legs, lungs, heart, brain, or abdominal blood vessels. Symptoms such as sudden chest pain, shortness of breath, one-sided weakness, difficulty speaking, severe headache, or painful swelling in one leg require urgent medical assessment.

Bleeding can also occur, especially when platelet function is abnormal or when blood counts are very high. Some patients may experience nosebleeds, gum bleeding, easy bruising, or gastrointestinal bleeding. The balance between preventing clots and avoiding bleeding is one reason treatment should be individualized and monitored by a hematologist.

Over years, a small proportion of patients may develop changes in the bone marrow, such as myelofibrosis, or rarely transformation to acute leukemia. These outcomes are not inevitable, but they are part of the reason for ongoing follow-up. Monitoring usually includes physical examination, review of symptoms, blood counts, and assessment of spleen size, treatment response, and side effects.

When to See a Doctor

A person should see a doctor if blood tests show persistently high hemoglobin or hematocrit, especially if accompanied by headaches, dizziness, itching after warm showers, unusual redness of the skin, or unexplained fatigue. Medical evaluation is also important if there is an enlarged spleen, unexplained clot, or high platelet or white blood cell count.

Urgent care is needed for symptoms that may suggest a clot, stroke, heart attack, or serious bleeding. These include sudden weakness or numbness on one side, trouble speaking, sudden vision loss, chest pain, coughing blood, severe shortness of breath, black stools, vomiting blood, or painful swelling in a limb. Prompt evaluation can improve safety and guide treatment.

People diagnosed with Polycythemia Vera should have regular follow-up with a hematologist, even when they feel well. Treatment needs may change over time, and blood count targets should be reviewed periodically. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat blood disorders, including Polycythemia Vera, for international patients seeking coordinated hematology care.

Frequently asked questions

Is Polycythemia Vera a type of cancer?

Polycythemia Vera is classified as a myeloproliferative neoplasm, which means it is a chronic disorder of blood-forming cells in the bone marrow. It often behaves slowly and can be managed for many years. The term can sound concerning, but many patients live active lives with regular monitoring and treatment.

Why is thick blood a problem in Polycythemia Vera?

When there are too many red blood cells, the blood becomes more viscous, or thicker. This can slow blood flow and make clots more likely to form. Treatment aims to lower the hematocrit and reduce the chance of complications such as stroke, heart attack, or deep vein thrombosis.

What is phlebotomy, and does it cure Polycythemia Vera?

Phlebotomy is the removal of a measured amount of blood to reduce the red blood cell mass and lower hematocrit. It is a common and effective way to control thick blood, but it does not cure the underlying bone marrow disorder. Many patients need repeated phlebotomy or additional treatment over time.

Does everyone with Polycythemia Vera need medication?

Not everyone needs medicines that suppress blood cell production. Some lower-risk patients may be managed with phlebotomy and low-dose aspirin if appropriate. Higher-risk patients, or those with difficult symptoms or blood counts, may need additional medication chosen by a hematologist.

Can lifestyle changes control Polycythemia Vera?

Lifestyle changes cannot correct the JAK2-related bone marrow activity that usually causes Polycythemia Vera. However, healthy habits can reduce additional clotting risks and support overall cardiovascular health. Staying active, avoiding smoking, managing blood pressure, and keeping follow-up appointments are all helpful.

How often should blood counts be checked?

The schedule depends on the stage of treatment, blood count stability, symptoms, and medications. Checks are often more frequent when treatment is starting or changing, and less frequent once counts are stable. The treating hematologist should set an individualized monitoring plan.

Can Polycythemia Vera turn into another blood disease?

In some patients, Polycythemia Vera can evolve over time into myelofibrosis, and rarely into acute leukemia. This does not happen to everyone, and the risk varies by individual factors and disease course. Regular monitoring helps doctors detect changes early and adjust care when needed.

References

• National Heart, Lung, and Blood Institute
• American Society of Hematology
• European LeukemiaNet
• National Comprehensive Cancer Network
• World Health Organization

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.